Mechanism-based pharmacodynamic modeling of S(-)-atenolol: Estimation of in vivo affinity for the β1-adrenoceptor with an agonist-antagonist interaction model

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 3, 2008, Pages 1234-1242

  Van Steeg, Tamara J ^a   Freijer, Jan ^b   Danhof, Meindert ^a   De Lange, Elizabeth C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LAP and P Consultants BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; ISOPRENALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEART RATE; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TACHYCARDIA;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATENOLOL; MALE; MODELS, BIOLOGICAL; PROTEIN BINDING; RATS; RATS, INBRED WKY; RECEPTORS, ADRENERGIC, BETA-1; STATISTICS AS TOPIC; STEREOISOMERISM;

EID: 40849126884     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.131680     Document Type: Article

References (40)

1. Akaike H (1974) A new look at the statistical model identification. IEEE (Inst Electr Electron Eng) Trans Automatic Control 19:716-723.
2. Appel S, Mathôt RA, Langemeijer MW, IJzerman AP, and Danhof M (1995) Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. Br J Pharmacol 115:1253-1259.
3. Ariens EJ (1954) Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharmacodyn Ther 99:32-49.
4. Beal SL and Sheiner LB (1999) NONMEM Users Guide. University of California at San Francisco, San Francisco.
5. Belpaire FM, Rosseel MT, Vermeulen AM, De Smet F, and Bogaert MG (1993) Stereoselective pharmacokinetics of atenolol in the rat: influence of aging and of renal failure. Mech Ageing Dev 67:201-210.
6. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
7. Chiu CC, Lin YT, Tsai CH, Liang JC, Chiang LC, Wu JR, Chen IJ, and Yeh JL (2000) Pharmacological effects of an aldehyde type α/β-adrenoceptor blocking agent with vasodilating properties. Gen Pharmacol 34:391-400.
8. Copeland RA, Pompliano DL, and Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-739.
9. Danhof M, De Jongh J, de Lange EC, Della Pasqua O, Ploeger BA, and Voskuyl RA (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357-400.
10. de Lange EC, Danhof M, de Boer AG, and Breimer DD (1994) Critical factors of intracerebral microdialysis as a technique to determine the pharmacokinetics of drugs in rat brain. Brain Res 666:1-8.
11. Doggrell SA, Petcu EB, and Barnett CW (1998) Affinity constants and beta-adrenoceptor reserves for isoprenaline on cardiac tissue from normotensive and hypertensive rats. J Pharm Pharmacol 50:215-223.
12. Doggrell SA and Surman AJ (1994) Functional beta-adrenoceptors in the left atrium of normotensive and hypertensive rats. J Auton Pharmacol 14:425-436.
13. Hardman JG, Limbird LE, and Gilman AG (2001) Goodman & Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill, New York.
14. Henry R, Casto R, and Printz M (1990) Diurnal cardiovascular patterns in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 16:422-428.
15. Jindal DP, Coumar MS, Nandakumar K, Bodhankar SL, Purohit PG, Mahadik KR, Bruni G, Collavoli E, and Massarelli P (2003) Synthesis, β-adrenergic blocking activity and β-receptor binding affinities of 1-substituted-3-(2- isopropyl-5-methylphenoxy)-propan-2-ol oxalates. Farmaco 58:557-562.
16. Kenakin TP (1993) Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott Williams & Wilkins, Philadelphia, PA.
17. Kirch W and Gorg KG (1982) Clinical pharmacokinetics of atenolol-a review. Eur J Drug Metab Pharmacokinet 7:81-91.
18. Leff P, Prentice DJ, Giles H, Martin GR, and Wood J (1990) Estimation of agonist affinity and efficacy by direct, operational model-fitting. J Pharmacol Methods 23:225-237.
19. Lipworth BJ, Irvine NA, and McDevitt DG (1991) A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol 40:135-139.
20. Louis SN, Nero TL, Iakovidis D, Jackman GP, and Louis WJ (1999) LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol 367:431-435.
21. Lu XY and Barnett DB (1990) Differential rates of down regulation and recovery of rat myocardial beta-adrenoceptor subtypes in vivo. Eur J Pharmacol 182:481-486.
22. Mandema JW, Tukker E, and Danhof M (1992) In vivo characterization of the pharmacodynamic interaction of a benozdiazepine agonist and antagonist: midazolam and flumazenil. J Pharmacol Exp Ther 260:36-44.
23. Mathôt RA, Van Schaick EA, Langemeijer MW, Soudijn W, Breimer DD, IJzerman AP, and Danhof M (1994) Pharmacokinetic-Pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther 268:616-624.
24. Matthews JM, Falckh PH, Molenaar P, and Summers RJ (1996) Chronic (-)-isoprenaline infusion down-regulates beta 1- and beta 2-adrenoceptors but does not transregulate muscarinic cholinoceptors in rat heart. Naunyn Schmiedebergs Arch Pharmacol 353:213-225.
25. Mehvar R, Gross ME, and Kreamer RN (1990) Pharmacokinetics of atenolol enantiomers in humans and rats. J Pharm Sci 79:881-885.
26. 1-adrenoreceptor blocking activity of newly synthesized acyl amino-substituted aryloxypropanolamine derivatives, DPJ 955 and DPJ 890, in rats. J Pharm Pharmacol 57:515-520.
27. Piercy V (1988) Method for assessing the activity of drugs at beta 1- and beta 2-adrenoceptors in the same animal. J Pharmacol Methods 20:125-133.
28. Rang H, Dale M, and Ritter J (1999) Pharmacology. Lippincott Williams & Wilkins, Philadelphia, PA.
29. Reeves PR, Barnfield DJ, Longshaw S, McIntosh DA, and Winrow MJ (1978a) Disposition and metabolism of atenolol in animals. Xenobiotica 8:305-311.
30. Reeves PR, McAinsh J, McIntosh DA, and Winrow MJ (1978b) Metabolism of atenolol in man. Xenobiotica 8:313-320.
31. Reiter MJ (2004) Cardiovascular drug class specificity: beta-blockers. Progr Cardiovasc Dis 47:11-33.
32. Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol Chemother 11:379-393.
33. Sweetnam PM, Caldwell L, Lancaster J, Bauer C Jr, McMillan B, Kinnier WJ, and Price CH (1993) The role of receptor binding in drug discovery. J Nat Prod 56:441-455.
34. Van Bortel LM, de Hoon JN, Kool MJ, Wijnen JA, Vertommen CI, and Van Nueten LG (1997) Pharmacological properties of nebivolol in man. Eur J Clin Pharmacol 51:379-384.
35. van den Buuse M (1999) Circadian rhythms of blood pressure and heart rate in conscious rats: effects of light cycle shift and timed feeding. Physiol Behav 68:9-15.
36. Van Der Graaf PH and Danhof M (1997a) Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. Int J Clin Pharmacol Ther 35:442-446.
37. Van der Graaf PH, van Schaick EA, Mathôt RA, IJzerman AP, and Danhof M (1997b) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J Pharmacol Exp Ther 283:809-816.
38. van Steeg TJ, Freijer J, Danhof M, and de Lange EC (2007) Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint. Br J Pharmacol 151:356-366.
39. Wellstein A, Palm D, Belz GG, Butzer R, Polsak R and Pett B (1987) Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. Eur Heart J 8 (Suppl M):3-8.
40. Zuideveld KP, Treijtel N, Maas HJ, Gubbens-Stibbe JM, Peletier LA, Van der Graaf PH, and Danhof M (2002) A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n- propylamino)tetralin-induced hypothermia. J Pharmacol Exp Ther 300:330-338.